查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1820098

2025-2033 年放射性药物市场报告（按产品类型、应用、最终用途和地区）

Radiopharmaceuticals Market Report by Product Type, Application, End Use, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 149 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球放射性药物市场规模达58亿美元。展望未来， IMARC Group预计到2033年，市场规模将达到89亿美元，2025-2033年期间的复合年增长率（CAGR）为4.9%。放射性药物市场的主要驱动力包括影像技术的新兴技术进步、慢性病发病率的上升以及全球各国政府实施有利的监管标准。

放射性药物市场趋势：

成像技术的技术进步：

正子断层扫描 (PET) 和单光子发射电脑断层扫描 (SPECT) 等影像技术的进步大大提高了放射性药物的诊断效能。使用这些技术对于早期诊断肿瘤学、神经病学和心臟病学中需要早期治疗或预防措施的疾病至关重要。例如，2023 年全球正子断层扫描 (PET) 市场价值约为 119.61 万美元。目前，根据 IMARC GROUP 的预测，全球正子断层扫描 (PET) 市场预计到 2032 年将成长到约 19.3 亿美元，2024 年至 2032 年的年复合成长率(CAGR) 为 5.33%。成长归因于影像技术的进步以及这些先进系统在世界各地医疗诊断中的应用。

慢性病盛行率不断上升：

全球癌症、心血管疾病和神经系统疾病的发生率不断上升，导致对放射性药物的需求不断增长，从而推动了市场的成长。这些疾病需要精确的诊断影像和有针对性的治疗，这促使放射性药物在临床实践中的应用。根据美国疾病管制与预防中心2020年的资料，美国报告了1,603,844例新发癌症病例，并有602,347人不幸死于癌症。这相当于每10万人中有403例新发癌症病例和144例癌症相关死亡病例。目前，放射性药物用于癌症早期发现和治疗所必需的诊断和治疗应用，从而推动了市场的成长。

有利的监管环境：

该行业受到政府行动和监管规定的显着影响。例如，美国食品药物管理局 (FDA) 和欧洲药品管理局 (EMA) 等监管机构根据美国国家医学图书馆 (NALMA) 的数据，制定了快速有效的审批程序，以批准新开发的放射性药物，鼓励创新和投资。此外，快速虚拟审查药物类别的可能性，以及获得孤儿药资格认定 (ODD) 资格的经济激励，促使许多製药公司参与新型放射性药物疗法的研发 (R&D)。

放射性药物市场细分：

按产品类型细分：

  • 诊断核子医学
  • 治疗核子医学

诊断核医学占大部分市场份额

诊断性核子医学是指使用多种通常用于影像的放射性药物。它包含多种不同的影像模式，例如正子断层扫描 (PET)。单光子发射电脑断层扫描 (SPECT) 也同样适用。由于癌症、心臟异常和其他神经疾病等疾病的发生率不断上升，诊断性核子医学市场在未来几年必将扩大。目前，纳格浦尔的政府医学院暨医院 (GMCH) 和高级专科医院 (SSH) 正准备成立专门的核子医学科，以提升其诊断能力。该科室的设立提案已于今年获得地区规划委员会 (DPC) 批准，预算为 9.5 亿卢比。由于行政管理部分已完成，该科室的建设即将启动。

按应用分类：

  • 肿瘤学
  • 心臟病学
  • 神经病学
  • 内分泌学
  • 其他的

肿瘤学占产业最大份额

随着标靶癌症治疗和精准医疗市场的快速成长，放射性药物在肿瘤学应用的需求日益增长。放射性药物在癌症的诊断、分期和治疗后评估（例如透过PET和SPECT扫描）中发挥着至关重要的作用。这也得益于不断扩张的放射肿瘤学市场，根据IMARC GROUP预测，到2032年，该市场规模将达到145亿美元，2024-2032年间的复合年增长率（CAGR）为6.5%。此外，持续进行的旨在提高放射性药物在肿瘤学中的可行性和安全性的研发工作预计将推动该产业的发展动能。

依最终用途分类：

  • 医院和诊所
  • 研究机构
  • 诊断中心

诊断中心代表着领先的细分市场

诊断中心占据了最大的市场份额，并正在创造良好的放射性药物市场前景。随着核子造影程序对各种疾病进行准确诊断的需求不断增长，诊断中心应运而生。它使用各种成像技术，例如正电子发射断层扫描 (PET)、单光子发射电脑断层扫描 (SPECT) 和混合成像，以确保良好的患者预后。因此，各主要参与者正在引入先进的诊断技术，这进一步扩大了放射性药物的市场价值。例如，2022 年 12 月，领先的医学影像技术公司 Polarean Imaging plc 宣布，美国食品药物管理局 (FDA) 批准了 XENOVIEW。它是一种超极化造影剂，适用于磁振造影 (MRI)，以评估成人和 12 岁及以上儿童患者的肺部通气。 XENOVIEW 代表了肺部医学的新时代，因为它是第一个吸入式 MRI 超极化造影剂。它能够以全新的方式可视化肺通气情况，而无需患者暴露于电离辐射及其相关风险。 XENOVIEW 透过 Polarean HPX 超极化系统进行给药，在单次屏气 MRI 检查中即可完成，每次检查持续 10-15 秒。

按地区划分：

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

北美引领市场，占据最大的放射性药物市场份额

该报告还对所有主要区域市场进行了全面分析，包括北美（美国和加拿大）；欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。报告指出，北美是放射性药物最大的区域市场。

北美凭藉其强大的医疗基础设施、高昂的医疗支出、先进的技术以及众多产品供应的成熟市场参与者，在市场中占据主导地位。根据美国医疗保险和医疗补助服务中心的数据，美国医疗保健支出成长 4.1%，到 2022 年达到 4.5 兆美元，增幅高于 2021 年的 3.2%。此外，2022 年，投保人口比例达到 92%（创历史新高），私人医疗保险投保人数增加了 290 万，医疗补助参保人数增加了 610 万人。此外，政府的大量资金投入和支持以及疾病盛行率的上升也在推动市场成长。因此，这促进了该领域的创新，加速了新型有效产品的推出，从而提高了放射性药物市场的成长率。

（请注意，这只是关键参与者的部分名单，完整名单将在报告中提供。）

  • 目前，放射性药物市场的主要参与者正采取各种策略性倡议，以维持其市场地位和立足点。这些措施包括投入研发资金，以开发和创新具有更高功效和安全性的新型放射性药物产品。除了研发和创新之外，这些公司还参与策略合作和伙伴关係，以扩展其产品线和分销网络。例如，2023年11月，总部位于威斯康辛州的核融合技术公司SHINE Technologies最近与Nucleus RadioPharma签订了一项长期供应协议，供应镕-177。镥-177是一种放射性同位素，用于癌症治疗，包括正在开发的神经内分泌肿瘤、前列腺癌和其他实体肿瘤的疗法。未来几年，SHINE将供应镥-177，以支持Nucleus RadioPharma的放射性配体疗法(RLT)产品，该产品针对专门针对神经内分泌肿瘤和前列腺癌的放射性药物治疗。一些关键参与者也参与加强和优化製造生产流程，以满足即将推出和现有的监管标准对放射性药物日益增长的需求。

本报告回答的关键问题

  • 2024年全球放射性药物市场规模是多少
  • 2025-2033年全球放射性药物市场的预期成长率是多少
  • COVID-19 对全球放射性药物市场有何影响
  • 推动全球放射性药物市场的关键因素有哪些
  • 根据产品类型，全球放射性药物市场如何划分
  • 根据应用，全球放射性药物市场如何划分
  • 根据最终用途，全球放射性药物市场如何划分
  • 全球放射性药物市场的主要区域有哪些
  • 全球放射性药物市场的主要参与者/公司有哪些

本报告回答的关键问题

  • 2024年全球放射性药物市场规模？ 2025-2033年全球放射性药物市场的预期成长率是多少？
  • COVID-19 对全球放射性药物市场有何影响？
  • 推动全球放射性药物市场发展的关键因素有哪些？
  • 根据产品类型，全球放射性药物市场是如何分布的？
  • 根据应用，全球放射性药物市场是如何分布的？
  • 根据最终用途，全球放射性药物市场是如何分類的？
  • 全球放射性药物市场的主要区域有哪些？
  • 全球放射性药物市场的主要参与者/公司有哪些？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 二手资料
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球放射性药物市场

  • 市场概况
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依产品类型

  • 诊断核子医学
  • 治疗核子医学

第七章：市场区隔：依应用

  • 肿瘤学
  • 心臟病学
  • 神经病学
  • 内分泌学
  • 其他的

第 8 章：市场区隔：最终用途别

  • 医院和诊所
  • 研究机构
  • 诊断中心

第九章：市场细分：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 10 章：SWOT 分析

第 11 章：价值链分析

第 12 章：波特五力分析

第十三章：价格分析

第 14 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Advanced Accelerator Applications (Novartis AG)
    • Bayer AG
    • Bracco SpA
    • Cardinal Health Inc.
    • Curium Pharma
    • General Electric Company
    • IBA RadioPharma Solutions
    • Jubilant Pharma Limited
    • Lantheus Medical Imaging Inc
    • Nordion Inc. (Sotera Health)
    • NTP Radioisotopes SOC Ltd
    • PharmaLogic Holdings Corp.
    • Siemens AG
Product Code: SR112025A3906

The global radiopharmaceuticals market size reached USD 5.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 8.9 Billion by 2033, exhibiting a growth rate (CAGR) of 4.9% during 2025-2033. The radiopharmaceuticals market is primarily driven by the emerging technological advancements in imaging technology, the increasing incidences of chronic ailments, and the implementation of favorable regulatory standards by the government across the globe.

Radiopharmaceuticals Market Trends:

Technological Advancements in Imaging Technologies:

The advancements in imaging technologies, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), have highly enhanced the diagnostic nature of radiopharmaceuticals. It is vital in the early diagnosis of conditions that require early treatment or preventive measures in oncology, neurology, and cardiology, using these technologies. For instance, in 2023, the global market for positron emission tomography (PET) was valued at approximately $1.196.1 Million. Presently, the global positron emission tomography (PET) market is projected to grow to about $1.93 billion by 2032, with a compound annual growth rate (CAGR) of 5.33% from 2024 through 2032, according to forecasts by the IMARC GROUP. The growth is attributed to advances in imaging technology and the implementation of these advanced systems in medical diagnostics across the world.

Increasing Prevalence of Chronic Diseases:

The market growth is driven by the increasing demand for radiopharmaceuticals due to the rising prevalence of cancer, cardiovascular diseases, and neurological disorders worldwide. These diseases necessitate accurate diagnostic imaging and focused therapeutics, prompting the utilization of radiopharmaceuticals in clinical practice. According to CENTERS for DISEASE CONTROL AND PREVENTION data in 2020, the United States witnessed the reporting of 1,603,844 new incidences of cancer and the unfortunate loss of 602,347 lives due to the disease. This equates to a rate of 403 new cancer cases and 144 cancer-related deaths per 100,000 individuals. Currently, radiopharmaceuticals are used in diagnostic and treatment applications necessary for the early detection and treatment of cancers, thus driving market growth.

Favorable Regulatory Environment:

The industry is significantly impacted by governmental actions and regulatory provisions. For instance, regulatory authorities such as the U.S. FOOD AND DRUG ADMINISTRATION (FDA) and the EUROPEAN MEDICINES AGENCY (EMA) present instant and effective procedures to approve newly developed radiopharmaceuticals encouraging innovation and investment as per the NATIONAL LIBRARY of MEDICINE. Besides this, the possibility of a rapid virtual review of drug classes, along with financial incentives for obtaining Orphan Drug Designation (ODD) status, motivates many pharmaceutical companies to engage in research and development (R&D) of new radiopharmaceutical therapies.

Radiopharmaceuticals Market Segmentation:

Breakup by Product Type:

  • Diagnostic Nuclear Medicine
  • Therapeutic Nuclear Medicine

Diagnostic nuclear medicine accounts for the majority of the market share

Diagnostic nuclear medicine refers to the administration of a diverse number of radiopharmaceuticals typically used for imaging. It incorporates different modalities such as positron emission tomography (PET). The same also applies to single-photon emission computed tomography (SPECT). Due to the observed increase in the prevalence of diseases including cancer, cardiac abnormalities, and other neuronal conditions, the diagnostic nuclear medicine market is bound to expand in the coming years. At present, the Government Medical College and Hospital (GMCH) and the Super Speciality Hospital (SSH) in Nagpur are preparing to elevate their diagnostic capabilities by launching a dedicated nuclear medicine department. The proposal for this department was approved by the District Planning Committee (DPC) this year with a 9.5 crore budget. Since the administrative part has been sorted, the construction of the department is to be initiated soon.

Breakup by Application:

  • Oncology
  • Cardiology
  • Neurology
  • Endocrinology
  • Others

Oncology holds the largest share of the industry

Oncology applications in radiopharmaceuticals are experiencing rising demand, facilitated by the rapid growth of the targeted cancer therapies and precision medicine market. Radiopharmaceuticals are crucial in the diagnosis, staging, and post-treatment evaluation of cancers through PET and SPECT scans, among other modalities. This is also attributed to the expanding radiation oncology market which is expected to reach US$ 14.5 Billion by 2032, exhibiting a growth rate (CAGR) of 6.5% during 2024-2032 as stated by IMARC GROUP. Apart from this, ongoing research and development efforts to improve the feasibility and safety of radiopharmaceuticals in oncology are anticipated to boost the momentum of the sector.

Breakup by End Use:

  • Hospitals and Clinics
  • Research Institutes
  • Diagnostic Centers

Diagnostic centers represent the leading market segment

Diagnostic centers represent the largest segment and are creating a favorable radiopharmaceuticals market outlook. The rising demand for nuclear imaging procedures to achieve an accurate diagnosis of various medical conditions resulted in the adoption of diagnostic centers. It uses various imaging techniques such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and hybrid imaging to ensure a favorable patient outcome. Hence various key players are introducing advanced diagnostic technologies which is further expanding the radiopharmaceuticals market value. For instance, in December 2022, Polarean Imaging plc, a leading medical imaging technology company, announced that the U.S. Food and Drug Administration (FDA) approved XENOVIEW. It is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) to assess lung ventilation in adults and pediatric patients 12 years of age and older. XENOVIEW represents a new era of pulmonary medicine since it is the very first inhaled MRI hyperpolarized contrast agent. It makes it possible to obtain a novel visualization of lung ventilation without exposing the patient to ionizing radiation and its associated risks. It is administered via the Polarean HPX hyperpolarization system, XENOVIEW is dispensed in a single 10-15 second breath hold MRI practice.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest radiopharmaceuticals market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for radiopharmaceuticals.

North America is dominating the market due to the presence of strong healthcare infrastructure, high healthcare spending, technological advancements, and the presence of established players within the market with numerous product offerings. According to the CENTERS FOR MEDICARE & MEDICAID SERVICES, United States health care spending grew 4.1% to reach $4.5 trillion in 2022, faster than the increase of 3.2% in 2021. Moreover, in 2022, the insured share of the population reached 92% (a historic high) and private health insurance enrollment increased by 2.9 million individuals and Medicaid enrollment increased by 6.1 million individuals. In addition, high government funding and support, as well as an increasing prevalence of disease, are also driving the market growth. Hence, this promotes innovation within the sector and accelerates the introduction of new and effective products generating an increasing radiopharmaceuticals market growth rate.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the radiopharmaceuticals industry include Advanced Accelerator Applications (Novartis AG), Bayer AG, Bracco S.p.A., Cardinal Health Inc., Curium Pharma, General Electric Company, IBA RadioPharma Solutions, Jubilant Pharma Limited, Lantheus Medical Imaging Inc, Nordion Inc. (Sotera Health), NTP Radioisotopes SOC Ltd, PharmaLogic Holdings Corp. and Siemens AG.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

  • Currently, key players in the radiopharmaceuticals market are involved in various strategic initiatives to sustain their market positions and footholds. These initiatives include research and development investments to develop and innovate new radiopharmaceutical products with enhanced efficacies and safety. In addition to research, development, and innovation, the companies are also involved in strategic collaborations and partnerships to expand their product pipeline and distribution networks. For instance, in November 2023, SHINE Technologies, a fusion technology company based in Wisconsin, has recently entered a long-term supply agreement with Nucleus RadioPharma to supply lutetium-177. A radioisotope is utilized in cancer treatment therapies, including those under development for neuroendocrine tumors, prostate cancer, and other solid tumors. For several years, SHINE will supply Lu-177 to support Nucleus RadioPharma's radioligand therapy (RLT) offerings, which target radiopharmaceutical treatments specifically designed for neuroendocrine tumors and prostate cancer. Some key players are also involved in enhancing and optimizing manufacturing production processes to meet the growing demand for radiopharmaceuticals in line with upcoming and existing regulatory standards.

Key Questions Answered in This Report

  • 1.What was the size of the global radiopharmaceuticals market in 2024?
  • 2.What is the expected growth rate of the global radiopharmaceuticals market during 2025-2033?
  • 3.What has been the impact of COVID-19 on the global radiopharmaceuticals market?
  • 4.What are the key factors driving the global radiopharmaceuticals market?
  • 5.What is the breakup of the global radiopharmaceuticals market based on the product type?
  • 6.What is the breakup of the global radiopharmaceuticals market based on the application?
  • 7.What is the breakup of the global radiopharmaceuticals market based on the end use?
  • 8.What are the key regions in the global radiopharmaceuticals market?
  • 9.Who are the key players/companies in the global radiopharmaceuticals market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Radiopharmaceuticals Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Diagnostic Nuclear Medicine
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Therapeutic Nuclear Medicine
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Oncology
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cardiology
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Neurology
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Endocrinology
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End Use

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Research Institutes
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Diagnostic Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Advanced Accelerator Applications (Novartis AG)
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Bayer AG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bracco S.p.A.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 SWOT Analysis
    • 14.3.4 Cardinal Health Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Curium Pharma
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 General Electric Company
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 IBA RadioPharma Solutions
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Jubilant Pharma Limited
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Lantheus Medical Imaging Inc
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Nordion Inc. (Sotera Health)
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 SWOT Analysis
    • 14.3.11 NTP Radioisotopes SOC Ltd
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
    • 14.3.12 PharmaLogic Holdings Corp.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
    • 14.3.13 Siemens AG
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Radiopharmaceuticals Market: Major Drivers and Challenges
  • Figure 2: Global: Radiopharmaceuticals Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Radiopharmaceuticals Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Radiopharmaceuticals Market: Breakup by Product Type (in %), 2024
  • Figure 5: Global: Radiopharmaceuticals Market: Breakup by Application (in %), 2024
  • Figure 6: Global: Radiopharmaceuticals Market: Breakup by End Use (in %), 2024
  • Figure 7: Global: Radiopharmaceuticals Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Radiopharmaceuticals (Diagnostic Nuclear Medicine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Radiopharmaceuticals (Diagnostic Nuclear Medicine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Radiopharmaceuticals (Therapeutic Nuclear Medicine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Radiopharmaceuticals (Therapeutic Nuclear Medicine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Radiopharmaceuticals (Oncology) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Radiopharmaceuticals (Oncology) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Radiopharmaceuticals (Cardiology) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Radiopharmaceuticals (Cardiology) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Radiopharmaceuticals (Neurology) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Radiopharmaceuticals (Neurology) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Radiopharmaceuticals (Endocrinology) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Radiopharmaceuticals (Endocrinology) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Radiopharmaceuticals (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Radiopharmaceuticals (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Radiopharmaceuticals (Hospitals and Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Radiopharmaceuticals (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Radiopharmaceuticals (Research Institutes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Radiopharmaceuticals (Research Institutes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Radiopharmaceuticals (Diagnostic Centers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Radiopharmaceuticals (Diagnostic Centers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: North America: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: North America: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: United States: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: United States: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Canada: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Canada: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Asia-Pacific: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Asia-Pacific: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: China: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: China: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Japan: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Japan: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: India: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: India: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: South Korea: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: South Korea: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Australia: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Australia: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Indonesia: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Indonesia: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Others: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Others: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Europe: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Europe: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Germany: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Germany: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: France: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: France: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: United Kingdom: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: United Kingdom: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Italy: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Italy: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Spain: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Spain: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Russia: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Russia: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Others: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Others: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Latin America: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Latin America: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Brazil: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Brazil: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Mexico: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Mexico: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Others: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Others: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Middle East and Africa: Radiopharmaceuticals Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Middle East and Africa: Radiopharmaceuticals Market: Breakup by Country (in %), 2024
  • Figure 76: Middle East and Africa: Radiopharmaceuticals Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Global: Radiopharmaceuticals Industry: SWOT Analysis
  • Figure 78: Global: Radiopharmaceuticals Industry: Value Chain Analysis
  • Figure 79: Global: Radiopharmaceuticals Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Radiopharmaceuticals Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Radiopharmaceuticals Market Forecast: Breakup by Product Type (in Million USD), 2025-2033
  • Table 3: Global: Radiopharmaceuticals Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 4: Global: Radiopharmaceuticals Market Forecast: Breakup by End Use (in Million USD), 2025-2033
  • Table 5: Global: Radiopharmaceuticals Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Radiopharmaceuticals Market: Competitive Structure
  • Table 7: Global: Radiopharmaceuticals Market: Key Players